Previous 10 | Next 10 |
home / stock / xomap / xomap news
Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million c...
These July sample selections are the current top positive/negative forensic stocks out of 8,000 stocks based on combined scores from four top forensic algorithms. The January Positive Forensic portfolio is beating the S&P 500 by +1.59% YTD. The Negative portfolio is beating by +13...
While XOMA offers an investment into an important sector of healthcare, drug revenue royalties, the story is just beginning. From first glance, years of losses and flat revenues look poor, but something special is hidden underneath. Those looking to get in before the story plays o...
Earned a $2 million milestone from Rezolute as it dosed the final patient in a Phase 2 open-label study of RZ358 in patients with congenital hyperinsulinism in early 2022. Rezolute has announced its intention to move RZ358 into Phase 3 clinical development. Roche’s ...
The following slide deck was published by XOMA Corporation in conjunction with this event. For further details see: XOMA (XOMA) Investor Presentation - Slideshow
Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...
XOMA Preferred Shares Series A (NASDAQ:XOMAP) declares $0.5391/share quarterly dividend, in line with previous. Forward yield 8.21% Payable Jan. 18; for shareholders of record Jan. 4; ex-div Jan. 3. See XOMAP Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: ...
Half of my retirement savings is invested in two sectors. It's important to match your investment allocations to what will meet your goals and needs. Income investing provides extremely high levels of flexibility. For further details see: I Put Half Of My Retirement Savi...
Added six assets to its portfolio of potential milestone and royalty assets in 2021 Company earned $0.5 million milestone as Janssen asset entered Phase 3 development NIS793 in combination with standard of care chemotherapy was granted Orphan Drug Designation for the tre...
XOMA Preferred Shares Series A (XOMAP) declares $0.539/share quarterly dividend.Forward yield 8.3%Payable July 15; for shareholders of record July 2; ex-div July 1.See XOMAP Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: XOMA Preferred Shares Series A d...
News, Short Squeeze, Breakout and More Instantly...
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Company Name:
XOMAP Stock Symbol:
NASDAQ Market:
XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock Website:
2024-07-02 09:00:25 ET XOMA Corp (XOMAP) declaring a stock dividend of $0.53906 per share on Ex-Date : July 03, 2024. Shareholders on record as of July 03, 2024 are eligible for the dividend. The payment date is scheduled for July 15, 2024, and the declaration was officially made on...
EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals’ recent sale of its Priority Revie...
2024-05-26 12:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...